casopitant casopitant casopitant (inn),: 208 former tentative trade names rezonic (u.s.) and zunrisa (europe), is an nk1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. it was under development by glaxosmithkline. in july 2008, the company filed a marketing authorisation application with the european medicines agency. the application was withdrawn and development was discontinued in september 2009 because glaxosmithkline decided that further safety assessment was necessary. however, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed. casopitantclinical dataother namesgw679769; gw-679769; (2r,4s)-4-(4-acetylpiperazin-1-yl)-n--2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamideatc codea04ad13 (who) identifiers iupac name (2s,4s)-4-(4-acetyl-1-piperazinyl)-n-ethyl]-2-(4-fluoro-2-methylphenyl)-n-methyl-1-piperidinecarboxamide cas number414910-27-3pubchem cid23725089chemspider25069049unii3b03kpm27lkeggd06574chemblchembl2107320comptox dashboard (epa)dtxsid40961762 chemical and physical dataformulac30h35f7n4o2molar mass616.625 g·mol−13d model (jsmol)interactive image smiles cc1=c(c=cc(=c1)f)2c(ccn2c(=o)n(c)(c)c3=cc(=cc(=c3)c(f)(f)f)c(f)(f)f)n4ccn(cc4)c(=o)c inchi inchi=1s/c30h35f7n4o2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27h,7-12,17h2,1-4h3/t19-,25-,27+/m1/s1key:xggtzckqrwxchw-jrlvaejtsa-n (verify)